“Symptom and quality-of-life improvements were selective rather than uniform, and patient preferences were divided between active medications, highlighting interindividual variability in tolerability and perceived benefit. Treatment selection should be individualized based on clinical phenotype an...”
Uppal et al. (Fri,) studied this question.